Get started
Author

Samuel J. Holzmayer

Observed names: Holzmayer, Samuel, Holzmayer, Samuel Josua, Samuel Holzmayer
ORCID: 0009-0006-4513-2367
Observed ORCID: 0009-0006-4513-2367
OpenAlex ID: A5041598176
Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
2022 · Jenny N. H. G. Ho, Dominik Schmidt, et al. · Blood · 57
PDF
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
2023 · Jonas S. Heitmann, Claudia Tandler, et al. · Nature Communications · 35
PDF
The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas
2024 · Samuel J. Holzmayer, Kai Liebel, et al. · Frontiers in Immunology · 17
Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody
2024 · Sylwia A. Stefańczyk, Ilona Hagelstein, et al. · Blood Cancer Journal · 17
PDF
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer
2025 · Ramona Rudalska, Jule Harbig, et al. · Nature Cancer · 15
Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
2023 · Polina Kaidun, Samuel J. Holzmayer, et al. · International Journal of Molecular Sciences · 11
PDF
Casein kinase 1α essentially regulates thrombopoiesis by driving megakaryocyte maturation and cytoskeleton organization
2025 · Ferdinand Kollotzek, Kristina Mott, et al. · Blood · 7
Identification of CD105 (endoglin) as novel risk marker in CLL
2022 · Sarah M. Greiner, Melanie Märklin, et al. · Annals of Hematology · 4
PDF
Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
2021 · Kübra Kaban, Sarah M. Greiner, et al. · Diagnostics · 4
PDF
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia
2025 · Melissa Zwick, Bastian Zinkel, et al. · Cancer Research · 3
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer
2025 · Sylwia A. Stefańczyk, Xenija Kaiser, et al. · Frontiers in Immunology · 2
PDF
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts
2024 · Samuel J. Holzmayer, Joseph Kauer, et al. · Cancers · 1
PDF
Crosstalk between NFAT and NFκB Signaling Regulates NK Cell Immunosurveillance
2023 · Melanie Märklin, Samuel Holzmayer, et al. · Blood · 1
PDF
Abstract 2104: NK cell immunosurveillance of tumors is regulated by NFAT1 and NFAT2
2022 · Melanie Märklin, Samuel Holzmayer, et al. · Cancer Research · 1
Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3)
2026 · Sylwia Stefańczyk, Xenija Kaiser, et al. · ImmunoTargets and Therapy
Abstract 6082: Enhanced NK cell reactivity with Fc-optimized B7-H3 antibody for colorectal and non-small cell lung cancer
2025 · Sylwia Anna Stefanczyk, Xenija Kaiser, et al. · Cancer Research
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancer
2025 · Kaiser, Xenija, Hagelstein, Ilona, et al. · Universitätsbibliothek Tübingen
FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
2024 · Melissa Zwick, Bastian Zinkel, et al. · Blood
PDF
Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling
2024 · Samuel J. Holzmayer, Jonas Mauermann, et al. · Blood
965 NFAT2 drives the cytoskeletal remodeling of leukemia cells, which regulates their vulnerability to perforin-mediated killing
2023 · Samuel Holzmayer, Jonas Mauermann, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 2102: NFAT2 determines susceptibility of chronic lymphocytic leukemia cells to constitutive and Rituximab-induced NK cell killing
2022 · Samuel J. Holzmayer, Sarah M. Greiner, et al. · Cancer Research
Works count: 23
Citation count: 175
H-index: 7
I10-index: 6
Year
Topic
Type